Diabetes cell therapy: A decade later

Minerva Endocrinologica

Volumn 36, Issue 1, 2011, Pages 23-39

  Vantyghem, M C ^a   Balavoine, A S ^a   Caiazzo, R ^a   Kerr Conte, J ^a   Noel, C ^a   Pattou, F ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes mellitus; Islets of Langerhans transplantation; Tissue therapy

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; EVEROLIMUS; EXENDIN 4; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ALLOGENIC PANCREAS ISLET TRANSPLANTATION; ALLOTRANSPLANTATION; ANEMIA; AUTOLOGOUS PANCREAS ISLET TRANSPLANTATION; AUTOTRANSPLANTATION; BLEEDING; CLINICAL PROTOCOL; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; GALLBLADDER DISEASE; GLYCEMIC CONTROL; GRAFT REJECTION; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG TRANSPLANTATION; LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OVARY CYST; PANCREAS ISLET; PANCREAS ISLET REJECTION; PANCREAS ISLET TRANSPLANTATION; PORTAL VEIN THROMBOSIS; PROTEINURIA; QUALITY OF LIFE; REVIEW; SKIN CANCER; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79960010322     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. CITR: Collaborative Islet Transplant Registry. Annual Report 2009. NIKKD/NIH. [Internet]. Available from www.citregistry.org [cited 2011, Feb 14].
2. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8. (Pubitemid 30490390)
3. Alejandro R, Barton FB, Hering BJ, Wease S; The CITR Investigators. 2008 Update From the Collaborative Islet Transplant Registry. Transplantation 2008;86:1783-8.
4. Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005;365:1642-4.
5. Kumar AF, Gruessner RW, Seaquist ER Risk of glucose intolerance and diabetes in hemipancreatectomized donors selected for normal preoperative glucose metabolism. Diabetes Care 2008;31:1639-43.
6. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes 1988;37:413-20. (Pubitemid 18096377)
7. Vantyghem Mc, Hazzan M, Tourvieille S, Provost F, Perimenis P, Declerck N et al. Selection Of Diabetic Patients For Islet Transplantation :A Single-Center Experience. Diabetes Metab 2004;30:417-23. (Pubitemid 39648009)
8. Federlin K, Pozza G. Indications for clinical islet transplantation today and in the forseeable future-the diabetologist's point of view. J Mol Med 1999;77:148-52. (Pubitemid 29146206)
9. Squifflet JP, Gruessner RW, Sutherland DE. The history of pancreas transplantation: past, present and future. Acta Chir Belg 2008;108:367-78.
10. Walter M, McDonald CG, Paty BW, Shapiro AM, Ryan EA, Senior PA. Prevalence of autoimmune diseases in islet transplant candidates with severe hypoglycaemia and glycaemic lability: previously undiagnosed coeliac and autoimmune thyroid disease is identified by screening. Diabet Med 2007;24:161-5. (Pubitemid 46174939)
11. Vantyghem MC, Press M. Management strategies for brittle diabetes. Ann Endocrinol (Paris). 2006;67:287-96.
12. Vantyghem MC, Marcelli-Tourvieille S, Fermon C, Duhamel A, Raverdy V, Arnalsteen L et al. Implantable pump versus islet insulin delivery: comparative study in type 1 diabetic patients. Transplantation 2009;87:66-71.
13. Gruessner RW, Sutherland DE, Kandaswamy R, Gruessner AC. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation 2008;85:42-7.
14. Kessler L, Greget M, Metivier AC, Moreau F, Bosco D, Santelmo N et al. Islet-lung transplantation with islet percutaneous portal embolization in cystic fibrosis. Transplantation 2008;85:1670-1.
15. Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008;86:1762-6.
16. Gerber PA, Pavlicek V, Demartines N, Zuellig R, Pfammatter T, Wüthrich R et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia 2008;51:110-9.
17. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-5. (Pubitemid 40250366)
18. Shapiro AM, Ricordi C, Hering B, Auchinclose H, Lindblat R, Robertson RP et al. International trial of the Edmonton protocol for islet transplantation N Engl J Med 2006;355:1318-30.
19. Badet L, Benhamou PY, Wojtusciszyn A, Baertschiger R, Milliat-Guittard L, Kessler L et al. GRAGIL Group. Expectation and strategies regarding islet transplantation : metabolic data from the GRAGIL 2 trial. Transplantation 2007;84:89-96.
20. Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005;5:2037-46. (Pubitemid 41039883)
21. Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbara B, Kuechle JB et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008;8:1250-61. (Pubitemid 351763686)
22. Huurman VA, Hilbrands R, Pinkse GG, Gillard P, Duinkerken G, van de Linde P et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation PLoS ONE 2008;3:e2435.
23. Bellin MD, Kandaswamy R, Parkey J, Zhang HJ, Liu B, Ihm SH et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008;8:2463-70.
24. Vantyghem MC, Kerr-Conte J, Arnalsteen L, Sergent G, Defrance F, Gmyr V et al. Primary graft function, metabolic control and graft survival after islet transplantation. Diabetes Care 2009;32:1473-8.
25. Lehmann R, Weber M, Berthold P, Züllig R, Pfammatter T, Moritz W et al. Successful simultaneous isletkidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am J Transplant 2004;4:1117-23. (Pubitemid 38868603)
26. Toso C, Baertschiger R, Morel P, Bosco D, Armanet M, Wojtusciszyn A et al. the GRAGIL group. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006;6:1049-58. (Pubitemid 44356657)
27. Cure P, Pileggi A, Froud T, Messinger S, Faradji RN, Baidal DA et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation 2008;85:801-12. (Pubitemid 351440744)
28. Lehmann R, Spinas GA, Moritz W, Weber M. Has Time come for new goals in human islet transplantation? Am J Transplant 2008;8:1096-100.
29. Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, Cure P et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005;80:1718-28. (Pubitemid 43053997)
30. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010;59:1285-91.
31. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care 2009;32:1563-9.
32. Khan MH, Harlan DM. Counterpoint: clinical islet transplantation: not ready for prime time. Diabetes Care 2009;32:1570-4.
33. Christoffersson G, Henriksnäs J, Johansson L, Rolny C, Ahlström H, Caballero-Corbalan J et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes 2010 Jul 22. [Epub ahead of print].
34. Echeverri GJ, McGrath K, Bottino R, Hara H, Dons EM, van der Windt DJ et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. Am J Transplant 2009;9:2485-96.
35. Senior PA, Zeman M, Paty B, Ryan EA, Shapiro AM. Changes in renal function after clinical islet transplantation:4-year observational study. Am J Transplant 2007;7:91-8. (Pubitemid 44952860)
36. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-64. (Pubitemid 36929282)
37. Fung MA, Warnock GL, Ao Z, Keown P, Meloche M, Shapiro RJ et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation 2007;84:17-22. (Pubitemid 47094636)
38. Rickels MR, Kamoun M, Kearns J, Markmann JF, Naji A. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab 2007;92:2410-4. (Pubitemid 47037334)
39. Campbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007;7:2311-7. (Pubitemid 47347848)
40. Cardani R, Pileggi A, Ricordi C, Gomez C, Baidal DA, Ponte GG et al. Allosensitization of islet allograft recipients. Transplantation 2007;84:1413-27.
41. Ferrari-Lacraz S, Berney T, Morel P, Marangon N, Hadaya K, Demuylder-Mischler S et al. Low risk of antihuman leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation 2008;86:357-9.
42. van Kampen CA, van de Linde P, Duinkerken G, van Schip JJ, Roelen DL, Keymeulen B et al. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005;80:118-26. (Pubitemid 40980904)
43. Campbell PM, Salam A, Ryan EA, Senior P, Paty BW, Bigam D et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007;7:1242-8. (Pubitemid 46643123)
44. Poggioli R, Faradji RN, Ponte G, Betancourt A, Messinger S, Baidal Dan et al. Quality of life after islet transplantation Am J Transplant 2006;6:371-8.
45. Toso C, Shapiro AM, Bowker S, Dinyari P, Paty B, Ryan EA et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome.Transplantation 2007;84:664-6.
46. Tharavanij T, Betancourt A, Messinger S, Cure P, Leitao CB, Baidal DA et al. Improved long-term health-related quality of life after islet transplantation. Transplantation 2008;86:1161-7
47. Benhamou PY, Milliat-Guittard L, Wojtusciszyn A, Kessler L, Toso C, Baertschiger R et al. Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials. Diabet Med 2009;26:617-21.
48. Speight J, Reaney MD, Woodcock AJ, Smith RM, Shaw JA. Patient-reported outcomes following islet cell or pancreas transplantation (alone or after kidney) in Type 1 diabetes: a systematic review. Diabet Med 2010;27:812-22.
49. Del Carro U, Fiorina P, Amadio S, De Toni Franceschini L, Petrelli A, Menini S et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007;30:3063-9.
50. Thompson DM, Begg IS, Harris C, Ao Z, Fung MA, Meloche RM et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation 2008;85:1400-5.
51. Hering BJ, Cooper DK, Cozzi E, Schuurman HJ, Korbutt GS, Denner J et al. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - executive summary. Xenotransplantation 2009;16:196-202.
52. van der Windt DJ, Bottino R, Casu A, Campanile N, Smetanka C, He J et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009;9:2716-26.
53. Kerr-Conte J, Pattou F, Lecomte-Houcke M, Xia Y, Boilly B, Proye C et al. Ductal cyst formation in collagen-embedded adult human islet preparations. A means to the reproduction of nesidioblastosis in vitro. Diabetes 1996;45:1108-14.
54. Van Hoof D, D'Amour KA, German MS.Derivation of insulin-producing cells from human embryonic stem cells. Stem Cell Res 2009;3:73-87.
55. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008;26:443-52. (Pubitemid 351501814)
56. Calne RY, Gan SU, Lee KO. Stem cell and gene therapies for diabetes mellitus. Nat Rev Endocrinol 2010;6:173-7.
57. Butler AE, Cao-Minh L, Galasso R, Rizza RA, Corradin A, Cobelli C et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 2010;53:2167-76.
58. Hanley SC, Austin E, Assouline-Thomas B, Kapeluto J, Blaichman J, Moosavi M et al. {beta}-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 2010;151:1462-72.
59. Hubert T, Strecker G, Gmyr V, Arnalsteen L, Garrigue D, Ezzouaoui R et al. Acute insulin response to arginine in deceased donors predicts the outcome of human islet isolation. Am J Transplant 2008;8:872-6. (Pubitemid 351347745)
60. Faradji RN, Monroy K, Messinger S, Pileggi A, Froud T, Baidal DA et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007;7:303-8. (Pubitemid 46096323)
61. Ryan EA, Paty BW, Senior PA, Lakey JR, Bigam D, Shapiro AM. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care 2005;28:343-7. (Pubitemid 40170937)
62. Caumo A, Maffi P, Nano R, Bertuzzi F, Luzi L, Secchi A et al. Transplant estimated function: A simple index to evaluate beta-cell secretion after islet transplantation. Diabetes Care 2008;31:301-5. (Pubitemid 351213340)
63. Yamada Y, Fukuda K, Fujimoto S, Hosokawa M, Tsukiyama K, Nagashima K et al. SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 2006;74:222-6.
64. Robertson RP Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient. Diabetes 2007;56:2420-4.
65. Pattou F, Kerr-Conte J, Wild D Non invasive in vivo imaging of functional human beta cells transplanted in the brachioradial muscle with GLP-1 receptor scan New Engl J Med 2010 [Epub ahead of print].
66. Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Källen R et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002;360:2039-45. (Pubitemid 36026584)
67. Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation 2010;89:465-71.
68. Cui W, Angsana J, Wen J, Chaikof EL. Liposomal formulations of thrombomodulin increase engraftment after intraportal islet transplantation. Cell Transplant 2010 [Epub ahead of print].
69. Akima S, Hawthorne WJ, Favaloro E, Patel A, Blyth K, Mudaliar Y et al. Tirofiban and activated protein C synergistically inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from allogeneic islet cells exposure to human blood. Am J Transplant 2009;9:1533-40.
70. Kessler L, Parissiadis A, Bayle F, Moreau F, Pinget M, Froelich N et al. GRAGIL Study Group. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009;9:1961-6.
71. Eisenbarth GS, Stegall M. Islet and pancreatic transplantation - autoimmunity and alloimmunity. N Engl J Med 1996;335:888-90. (Pubitemid 26304075)
72. Vantyghem MC, Marcelli-Tourvielle S, Pattou F, Noël C. Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Ann Endocrinol (Paris) 2007;68:21-7. (Pubitemid 46616590)
73. Aasebø W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisaeter AV et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010;2:1289-93.
74. Marcelli-Tourvieille S, Hubert T, Moerman E, Nunes B, Kerr-Conte J, Vandewalle B. Sirolimus increases insulin secretion in vivo and in vitro at drug-plasma concentrations usually targeted in clinical practice. Transplantation 2007;83:532-8.
75. Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant 2010;10:1701-6.
76. Huang X, Moore DJ, Ketchum RJ, Nunemaker CS, Kovatchev B, McCall AL et al. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr Rev 2008;29:603-30.
77. Rother KI. Diabetes treatment - bridging the divide. N Engl J Med. 2007;356:1499-501 (Pubitemid 46588414)
78. Sutherland DE, Gruessner AC, Carlson AM, Blondet JJ, Balamurugan AN, Reigstad KF et al. islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. Transplantation. 2008;86:1799-802.